Northstar, fair enough, but can we also get some understanding of what work Pestell completed from about August 2018 when he was hired to June 2019. The question here, is was Nader rushing this protocol to make up for the prior year of lost time. Would the protocol as Pestell requested, have been perfectly reasonable but should have submitted 6 months prior.
Nader is in the wrong here what was Pestell doing all that time in a prerevenue biotech that was starved for funding and where the risk of BK and/or dilution is constant.